Words by Isabel O’Brien
Vantive, the newly independent kidney care specialist spun out from Baxter, has announced a major investment of more than $1bn over the next five years to expand its R&D and manufacturing capabilities. The move was unveiled in Vienna ahead of the company’s first appearance as a standalone entity at the 62nd European Renal Association (ERA) Congress.
The investment comes at a time when chronic kidney disease (CKD) is placing increasing strain on health systems. In Europe alone, the annual cost of CKD and end-stage renal disease is estimated to exceed €14bn. The prevalence of CKD is rising due to ageing populations and higher rates of diabetes and hypertension, with the disease projected to become the fifth leading cause of death globally by 2040.
Vantive’s stated focus is on accelerating the development of digitally-enabled therapies, such as remote patient management platforms and digital solutions for intensive care units. Its Sharesource Connectivity Platform enables patients undergoing at-home dialysis to stay connected with care teams, while the PrisMax System supports clinicians treating critically ill patients in hospitals.
Discussing the $1bn funding pledge, Chris Toth, CEO, Vantive, said: “As we prepare to take part in our first ERA Congress as Vantive, we are proud to unveil this significant investment, which underscores our commitment to shaping the future of kidney care and vital organ support.”
He added: “Better outcomes are possible when care is more accessible, more intuitive, and more connected to the needs of patients as well as the realities of the modern healthcare ecosystem. That’s why we are focused on transforming where and how therapy is delivered – from life-saving critical care for patients in a hospital, to life-sustaining dialysis for patients at home.”
Vantive will be offering product demonstrations at ERA 2025, where Toth is scheduled to share further insights into the company’s vision for the future of kidney care.
